CO4230233A1 - Derivados de benzofurano - Google Patents
Derivados de benzofuranoInfo
- Publication number
- CO4230233A1 CO4230233A1 CO94037843A CO94037843A CO4230233A1 CO 4230233 A1 CO4230233 A1 CO 4230233A1 CO 94037843 A CO94037843 A CO 94037843A CO 94037843 A CO94037843 A CO 94037843A CO 4230233 A1 CO4230233 A1 CO 4230233A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- atom
- hydrogen
- carbon
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REIVINDICACION NUMERO UN COMPUESTO DE LA FORMULA (I) FIGURA 1 CARACTERIZADO PORQUE R REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO AL- COXI DE 1 A 4 ATOMOS DE CARBONO R1 SE SELECCIONA DEL GRUPO QUE CONSISTE DE FENILO, OPCIONALMENTE SUSTITUIDO CON UN GRUPO -(CH2)nCON- R3R4 o S(O)nR3; O UN ANILLO HETEROCICLICO AROMATI- CO DE 5 O 6 MIEMBROS CONTENIDO 1, 2, 3 o 4 HETE- ROATOMOS QUE SE SELECCIONAN DEL GRUPO QUE CONSISTE DE OXIGENO, NITROGENO O AZUFRE, OPCIONALMENTE SUS- TITUIDO CON UN GRUPO ALQUILO DE 1 A 4 ATOMOS DE CARBONO, UN GRUPO TRIFLUOROMETILO O CIANO O UN GRUPO -(CH2)nCONR3R4; R2 REPRESENTA UN ATOMO DE HIDROGENO O HALOGENO; R3 Y R4, INDEPENDIENTEMENTE, REPRESENTAN UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO DE 1 A 4 ATOMOS DE CARBONO; n REPRESENTA 0, 1 o 2; m REPRESENTA 0, 1 o 2; x REPRESENTA O o 1; o UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO".
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939317987A GB9317987D0 (en) | 1993-08-26 | 1993-08-26 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4230233A1 true CO4230233A1 (es) | 1995-10-19 |
Family
ID=10741251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO94037843A CO4230233A1 (es) | 1993-08-26 | 1994-08-25 | Derivados de benzofurano |
Country Status (16)
Country | Link |
---|---|
US (1) | US5935972A (es) |
EP (1) | EP0783499B1 (es) |
JP (1) | JP3499243B2 (es) |
AP (1) | AP9400666A0 (es) |
AT (1) | ATE226578T1 (es) |
AU (1) | AU7655094A (es) |
CO (1) | CO4230233A1 (es) |
DE (1) | DE69431604T2 (es) |
EC (1) | ECSP941146A (es) |
ES (1) | ES2185665T3 (es) |
GB (1) | GB9317987D0 (es) |
IL (1) | IL110793A (es) |
IS (1) | IS4201A (es) |
PE (1) | PE14995A1 (es) |
WO (1) | WO1995006645A1 (es) |
ZA (1) | ZA946470B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
GB9505692D0 (en) * | 1995-03-21 | 1995-05-10 | Glaxo Group Ltd | Chemical compounds |
GB9513121D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
TW458774B (en) * | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
CA2255651A1 (en) * | 1996-06-26 | 1997-12-31 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
GB9614347D0 (en) * | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
DK1178984T3 (da) | 1999-05-21 | 2003-06-10 | Pfizer Prod Inc | 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater |
DE60012953T2 (de) * | 1999-10-07 | 2005-08-18 | Hisamitsu Pharmaceutical Co., Inc., Tosu | 3-amino-2-phenylpiperidinderivate als substanz p antagonisten |
EP1274424A4 (en) * | 2000-04-12 | 2003-09-17 | Smithkline Beecham Corp | CONNECTIONS AND PROCEDURE |
AU7552401A (en) * | 2000-06-12 | 2001-12-24 | Univ Rochester | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
KR20030064773A (ko) * | 2000-10-26 | 2003-08-02 | 툴라릭, 인코포레이티드 | 항염증제 |
AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
US7868016B2 (en) * | 2005-07-13 | 2011-01-11 | Baxter International Inc. | Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
RU2008116844A (ru) | 2005-09-29 | 2009-11-10 | Мерк энд Ко., Инк. (US) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2007107543A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
RS58936B1 (sr) | 2007-01-10 | 2019-08-30 | Msd Italia Srl | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物 |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
CN102595902B (zh) | 2009-05-12 | 2015-04-29 | 阿尔巴尼分子研究公司 | 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途 |
AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN108676800B (zh) | 2010-08-17 | 2022-11-11 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
EP2900241B1 (en) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
RU2660349C2 (ru) | 2012-11-28 | 2018-07-05 | Мерк Шарп И Доум Корп. | Композиции и способы для лечения злокачественной опухоли |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59186969A (ja) * | 1983-04-08 | 1984-10-23 | Yoshitomi Pharmaceut Ind Ltd | ベンゾフラン−およびベンゾピランカルボキサミド誘導体 |
US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
PT655996E (pt) * | 1992-08-19 | 2002-04-29 | Pfizer | Benzilaminas substituidas contendo heterociclicos nao aromaticos contendo azoto |
IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
-
1993
- 1993-08-26 GB GB939317987A patent/GB9317987D0/en active Pending
-
1994
- 1994-08-23 EC EC1994001146A patent/ECSP941146A/es unknown
- 1994-08-24 ZA ZA946470A patent/ZA946470B/xx unknown
- 1994-08-25 ES ES94926877T patent/ES2185665T3/es not_active Expired - Lifetime
- 1994-08-25 CO CO94037843A patent/CO4230233A1/es unknown
- 1994-08-25 WO PCT/EP1994/002804 patent/WO1995006645A1/en active IP Right Grant
- 1994-08-25 US US08/793,099 patent/US5935972A/en not_active Expired - Fee Related
- 1994-08-25 DE DE69431604T patent/DE69431604T2/de not_active Expired - Fee Related
- 1994-08-25 JP JP50792395A patent/JP3499243B2/ja not_active Expired - Fee Related
- 1994-08-25 AT AT94926877T patent/ATE226578T1/de not_active IP Right Cessation
- 1994-08-25 IS IS4201A patent/IS4201A/is unknown
- 1994-08-25 AU AU76550/94A patent/AU7655094A/en not_active Abandoned
- 1994-08-25 PE PE1994249244A patent/PE14995A1/es not_active Application Discontinuation
- 1994-08-25 EP EP94926877A patent/EP0783499B1/en not_active Expired - Lifetime
- 1994-08-25 AP APAP/P/1994/000666A patent/AP9400666A0/en unknown
- 1994-08-26 IL IL11079394A patent/IL110793A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69431604D1 (de) | 2002-11-28 |
DE69431604T2 (de) | 2003-06-26 |
EP0783499B1 (en) | 2002-10-23 |
PE14995A1 (es) | 1995-06-04 |
US5935972A (en) | 1999-08-10 |
IS4201A (is) | 1995-03-01 |
AP9400666A0 (en) | 1994-10-31 |
ECSP941146A (es) | 1995-01-16 |
GB9317987D0 (en) | 1993-10-13 |
WO1995006645A1 (en) | 1995-03-09 |
IL110793A0 (en) | 1994-11-11 |
ES2185665T3 (es) | 2003-05-01 |
AU7655094A (en) | 1995-03-22 |
EP0783499A1 (en) | 1997-07-16 |
ZA946470B (en) | 1995-11-14 |
JPH10508824A (ja) | 1998-09-02 |
ATE226578T1 (de) | 2002-11-15 |
JP3499243B2 (ja) | 2004-02-23 |
IL110793A (en) | 1998-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4230233A1 (es) | Derivados de benzofurano | |
ES2196344T3 (es) | Derivados de sulfonamida y su uso en el tratamiento de trastornos de snc. | |
NO941210L (no) | Benzo- og pyrido-pyridazinonforbindelser og -pyridazintionforbindelser | |
CO4410319A1 (es) | Derivados de fenetanolamina | |
NO306510B1 (no) | Androsteroner, anvendelse derav og farmasöytisk formulering | |
ATE49211T1 (de) | Dreizyklische oxindole als antientzuendungsmittel. | |
ATE115136T1 (de) | 4-phenylphthalazin-derivate. | |
DE69202120D1 (de) | Harnstoffderivate, ihre Herstellung und ihre Verwendung bei der Therapie. | |
DE59209553D1 (de) | 1,7-anellierte 3-(Piperazino-alkyl)indol-Derivate sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
ES2141096T3 (es) | Compuestos de cefalosporina y composiciones farmaceuticas de los mismos. | |
ES2051674T1 (es) | Derivados de benzoaxin y benzotiazin dotados de actividad cardiovascular. | |
ES2158290T3 (es) | Derivados de tiazolidinona opticamente activos. | |
FI961793A0 (fi) | Muistia parantavina aineina käyttökelpoiset 3-aryyli-4-alkyyli- ja 4,5-dialkyyli 4H-1,2,4-triatsolit | |
SE8802162L (sv) | Nya aminoacylater av glycerolacetal | |
ATE113047T1 (de) | 2-fluorneplanocin a und seine herstellung. | |
TH23430A (th) | อนุพันธ์ของอีเธอร์ |